- Previous Close
1.3300 - Open
1.3300 - Bid --
- Ask --
- Day's Range
1.3163 - 1.3350 - 52 Week Range
1.2200 - 1.9400 - Volume
12,549 - Avg. Volume
127,098 - Market Cap (intraday)
63.701M - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0200 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.00
Ikena Oncology, Inc. operates as an oncology company in the United States. The company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. The company develops IK-595, a molecular glue which is in Phase 1 clinical trial to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts
ikenaoncology.comRecent News: IKNA
View MorePerformance Overview: IKNA
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IKNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IKNA
View MoreValuation Measures
Market Cap
63.70M
Enterprise Value
-53.16M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.51
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.44%
Return on Equity (ttm)
-33.30%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-49.23M
Diluted EPS (ttm)
-1.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
124.39M
Total Debt/Equity (mrq)
5.97%
Levered Free Cash Flow (ttm)
-31.55M